603998.SHG Hunan Fangsheng Pharm Co Ltd
- Market cap
- CNY 4.53B
- P/E
- 13.6x
- P/B
- 2.49x
- ROE
- 21.6%
- Dividend yield
- 4.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603998.SHG undervalued?
Graham number603998.SHG trades 22.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Fangsheng Pharm Co Ltd fundamental analysis
No fundamental analysis for Hunan Fangsheng Pharm Co Ltd yet.
Hunan Fangsheng Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, neurological drugs, gynecological drugs, and anti-infective drugs. Its products include Xuesaitong dispersible tab…
Full company profileHunan Fangsheng Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Fangsheng Pharm Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 534M | 721M | 1.05B | 1.09B | 1.28B | 1.57B | 1.79B | 1.63B | 1.78B | 1.75B | 1.85B |
| Gross Profit | 263M | 431M | 776M | 793M | 811M | 1.00B | 1.20B | 1.11B | 1.26B | 1.26B | 1.39B |
| Operating Income | 84.2M | 80.2M | 92.1M | 96.4M | 72.4M | 99.7M | 332M | 196M | 285M | 326M | 440M |
| EBITDA | 116M | 122M | 142M | 159M | 157M | 177M | 419M | 296M | 381M | 449M | 463M |
| Net Income | 69.8M | 59.7M | 73.0M | 78.9M | 63.8M | 70.0M | 286M | 187M | 255M | 306M | 385M |
| EPS | 0.16 | 0.14 | 0.17 | 0.18 | 0.15 | 0.16 | 0.66 | 0.42 | 0.58 | 0.70 | 0.88 |
| Balance Sheet | |||||||||||
| Total Assets | 1.27B | 1.37B | 1.64B | 1.99B | 2.24B | 2.70B | 2.92B | 3.08B | 3.27B | 3.06B | 3.06B |
| Total Liabilities | 291M | 335M | 530M | 793M | 977M | 1.40B | 1.41B | 1.49B | 1.53B | 1.25B | 1.19B |
| Shareholders' Equity | 928M | 985M | 1.05B | 1.13B | 1.15B | 1.20B | 1.39B | 1.46B | 1.62B | 1.71B | 1.78B |
| Cash & Short-term Investments | 363M | 141M | 318M | 156M | 319M | 274M | 440M | 229M | 308M | 276M | 198M |
| Total Debt | 65.2M | 66.3M | 180M | 306M | 439M | 533M | 530M | 483M | 697M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 119M | 16.0M | 176M | 163M | 237M | 186M | 302M | 87.5M | 195M | 385M | - |
| Capital Expenditure | 167M | 133M | 74.9M | 199M | 168M | 185M | 171M | 219M | 94.8M | 103M | 86.4M |
| Free Cash Flow | -48.6M | -117M | 101M | -36.9M | 68.9M | 916K | 130M | -131M | 100M | 282M | 483M |
| Ratios | |||||||||||
| ROE | 7.5% | 6.1% | 6.9% | 7.0% | 5.5% | 5.9% | 20.6% | 12.8% | 15.7% | 17.9% | 21.6% |
| ROA | 5.5% | 4.3% | 4.4% | 4.0% | 2.8% | 2.6% | 9.8% | 6.1% | 7.8% | 10.0% | 12.6% |
| Net Profit Margin | 13.1% | 8.3% | 6.9% | 7.2% | 5.0% | 4.5% | 16.0% | 11.5% | 14.4% | 17.5% | 20.9% |
| Debt to Equity | 0.07x | 0.07x | 0.17x | 0.27x | 0.38x | 0.45x | 0.38x | 0.33x | 0.43x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Fangsheng Pharm Co Ltd dividends
- Dividend yield
- 4.27%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 63.1%
- Ex-dividend date
- Sep 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 193M | 0.44 | 63.1% |
| 2024 | CNY 130M | 0.29 | 50.7% |
| 2023 | CNY 174M | 0.39 | 93.4% |
| 2022 | CNY 104M | 0.24 | 36.4% |
| 2021 | CNY 25.8M | 0.06 | 36.8% |
| 2020 | CNY 51.4M | 0.12 | 80.6% |
| 2019 | CNY 12.9M | 0.03 | 16.4% |
| 2018 | CNY 9.62M | 0.02 | 13.2% |
| 2017 | CNY 8.86M | 0.02 | 14.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on May 5, 2016.
Who owns Hunan Fangsheng Pharm Co Ltd
- Insiders 40.19%
- Institutions 8.66%
- Public & others 51.15%
- Shares outstanding 439M
- Free float 268M
Hunan Fangsheng Pharm Co Ltd company profile
- Company name
- Hunan Fangsheng Pharm Co Ltd
- Ticker
- 603998.SHG
- ISIN
- CNE100001VG6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,868
- Fiscal year end
- December
- Address
- No. 299, Jiayun Road, Changsha, China, 410205
- Phone
- 86 731 8890 8611
- Website
- fangsheng.com.cn
About Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, neurological drugs, gynecological drugs, and anti-infective drugs. Its products include Xuesaitong dispersible tablets; Xuesaitong tablets; Garcinia Cambogia bone strengthening tablets; Lysine Vitamin B12 granules; Cephalosporin tablets, Jinying capsules; Pudilan anti-inflammatory tablets; Tenghuang Jian Gu tablets; Xiaoer Jingxing Zhike granules; Yizhemaibu tablets; Xuanqi Jian tablets; Xuanqi Jian Gu tablets, Qiangli Pipa Gao, strong loquat syrup, and others. Hunan Fangsheng Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changsha, China.
Hunan Fangsheng Pharm Co Ltd management
4- Ms. Xiaoli ZhouGM & Chairman · born 1973
- Ms. Xiangqi CaoFinancial Director & Accounting Supervisor · born 1974
- Mr. Chen BoDeputy GM & Director · born 1979
- Mr. Shi HeBoard Secretary · born 1985